|
Dr. Vallner is Chairman and Chief Executive Officer of Plexera Bioscience LLC, Lumera’s wholly owned subsidiary. He has worked in the pharmaceutical industry as both academician and with commercial organizations. His most recent company affiliations have been Capnia, a private pharmaceutical development concern; Cell Genesys from 1999 until 2006 where he was President and Chief Operating Officer, responsible for research, development, clinical, regulatory, manufacturing and operations departments; Sequus Pharmaceuticals where he held various positions including Executive Vice-President and COO, and was instrumental in leading Sequus to the launch of two products including Doxil ®, a pegylated liposome-based cancer therapeutic. He also helped transition Sequus through its merger into Alza Corporation. He worked prior to Sequus with both Syntex and G.D.Searle and Company. His career began with the University of Georgia as an Assistant, then Associate Professor of Pharmaceutics. He obtained his Ph.D. in pharmaceutics and an MS in physical chemistry and BS in pharmacy from the University of Wisconsin, Madison. He has served on the California Healthcare Institute Board of Directors while at Cell Genesys. He serves on the Board for Lumera Corporation. | 